慢性乙型肝炎患者的管理和治疗：走向个性化医疗

StephenW

慢性乙型肝炎患者的管理和治疗：走向个性化医疗
皮耶罗·科隆巴托
1、芭芭拉可可
1 [ORCID]，费鲁乔·博尼诺
2 [ORCID] 和 Maurizia R. Brunetto
1,2,3,* [兽人]
1
肝病科和肝炎病毒分子遗传学和病理学实验室，托斯卡纳地区慢性肝病和癌症参考中心，比萨大学医院医学专科部，Via Paradisa 2, 56124 Pisa, Italy
2
国家研究委员会生物结构和生物成像研究所，Via De Amicis 95, 80145 那不勒斯，意大利
3
比萨大学临床和实验医学系内科, Via Savi 10, 56127 Pisa, Italy
*
通讯作者。
学术编辑：Pietro Andreone 和 Stefano Brillanti
病毒 2022, 14(4), 701; https://doi.org/10.3390/v14040701
收到日期：2022 年 2 月 13 日 / 修订日期：2022 年 3 月 22 日 / 接受日期：2022 年 3 月 23 日 / 发布日期：2022 年 3 月 28 日
（这篇文章属于特刊 病毒性肝炎治疗）
查看全文 下载 PDF 浏览图
引文导出
抽象的
目前可用的针对慢性乙型肝炎 (CHB) 的抗病毒治疗（Peg-干扰素-α 和核苷（酸）类似物，NA）在少数患者中实现了 HBV 感染的功能性治愈（血清 HBsAg 和 HDV-DNA 清除） .然而，NA 对病毒复制的持续药理学抑制阻止了肝病的进展，从而降低了 HCC 发展的风险并提高了生存率。在不久的将来，为了充分利用新旧药物治疗 HBV 的潜力，需要根据对患者病毒学、免疫学和临床特征的准确定义，为患者制定个性化的治疗方案。查看全文
关键词：乙肝；慢性乙型肝炎；干扰素-α；核苷（酸）类似物；抗病毒治疗； HBV功能性治愈

StephenW

Management and Treatment of Patients with Chronic Hepatitis B: Towards Personalized Medicine
by Piero Colombatto
1, Barbara Coco
1 [ORCID] , Ferruccio Bonino
2 [ORCID] and Maurizia R. Brunetto
1,2,3,* [ORCID]
1
Hepatology Unit and Laboratory of Molecular Genetics and Pathology of Hepatitis Viruses, Reference Center of the Tuscany Region for Chronic Liver Disease and Cancer, Department of Medical Specialties, University Hospital of Pisa, Via Paradisa 2, 56124 Pisa, Italy
2
Institute of Biostructure and Bioimaging, National Research Council, Via De Amicis 95, 80145 Naples, Italy
3
Internal Medicine, Department of Clinical and Experimental Medicine, University of Pisa, Via Savi 10, 56127 Pisa, Italy
*
Author to whom correspondence should be addressed.
Academic Editors: Pietro Andreone and Stefano Brillanti
Viruses 2022, 14(4), 701; https://doi.org/10.3390/v14040701
Received: 13 February 2022 / Revised: 22 March 2022 / Accepted: 23 March 2022 / Published: 28 March 2022
(This article belongs to the Special Issue Viral Hepatitis Treatment)
View Full-Text Download PDF Browse Figures
Citation Export
Abstract
The currently available antiviral treatments (Peg-Interferon-α and Nucleos(t)ide Analogues, NA) for chronic hepatitis B (CHB) achieve a functional cure (serum HBsAg and HDV-DNA clearance) of HBV infection in a limited number of patients. Nevertheless, the continuous pharmacological suppression of viral replication by NA halts liver disease progression lowering the risk of HCC development and improving the survival. In the near future, to fully exploit the potential of old and new drugs for HBV treatment a personalized approach to the patients will be required according to an accurate definition of their virologic, immunologic and clinical profile. View Full-Text
Keywords: HBV; chronic hepatitis B; Interferon-α; nucleos(t)ide analogues; antiviral treatment; HBV functional cure

StephenW

https://www.mdpi.com/1999-4915/14/4/701/pdf